ATHA Athira Pharma, Inc.

We are a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. With our product candidates, we aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule, for Alzheimer’s.

$12.60  -0.47 (-3.60%)
As of 12/03/2021 11:47:05 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  09/18/2020
Outstanding shares:  37,351,104
Average volume:  488,619
Market cap:   $462,406,668
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    04746L104
ISIN:        US04746L1044
Sedol:      BMTVQR6
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.45
PS ratio:   0.00
Return on equity:   -13.75%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy